Possible antiretroviral therapy-warfarin drug interaction

Pharmacotherapy

Volumn 28, Issue 7, 2008, Pages 945-949

  Pecora Fulco, Patricia ^a,b,c   Zingone, Michelle M ^a,b   Higginson, Robert T ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c NONE   (United States)

Author keywords

Anticoagulation; Drug interaction; HAART; Highly active antiretroviral therapy; Lopinavir ritonavir; Nelfinavir; Nevirapine; NNRTIs; Nonnucleoside reverse transcriptase inhibitors; Protease inhibitors; Warfarin

Indexed keywords

CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; ENOXAPARIN; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; WARFARIN;

ADULT; ARTICLE; CASE REPORT; DEEP VEIN THROMBOSIS; DISEASE COURSE; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFECT; DRUG MONITORING; DRUG WITHDRAWAL; ENANTIOMER; ENZYME INDUCTION; ENZYME INHIBITION; ENZYME SUBSTRATE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; MALE; PATIENT ASSESSMENT; PROBABILITY;

ADULT; ANTICOAGULANTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG COMBINATIONS; DRUG INTERACTIONS; HUMANS; MIDDLE AGED; NELFINAVIR; NEVIRAPINE; PROTEASE INHIBITORS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; WARFARIN;

EID: 45749145161     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.28.7.945     Document Type: Article

References (31)

1. U.S. Department of Health and Human Services, the Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Available from http://www.aidsinfo.nih.gov. Accessed December 1, 2007.
2. Cram NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons. J Acquir Immune Defic Syndr 2006;41:194-200.
3. Piscitelli SC, Gallicano KD. Interactions among drugs for HIV and opportunistic infections. N Engl J Med 2001;344:984-96.
4. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60.
5. Liedtke MD, Lockhart SM, Rathbun RC. Anticonvulsant and antiretroviral interactions. Ann Pharmacother 2004;38:482-9.
6. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
7. Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007;41:674-80.
8. Takahashi H, Echizen H. Pharmacogenetics of warfarin elimination and its clinical implications. Clin Pharmacokinet 2001;40:587-603.
9. Bristol-Myers Squibb. Coumadin (warfarin) package insert. Princeton, NJ; 2007.
10. Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 2005;165:1095-106.
11. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74.
12. Boehringer Ingelheim. Viramune (nevirapine) package insert. Ridgefield, CT; 2007.
13. Jaruratanasirikul S, Sriwiriyajan S. Pharmacokinetic study of the interaction between itraconazole and nevirapine. Eur J Clin Pharmacol 2007;63:451-6.
14. Dionisio D, Miminni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001;15:277-8.
15. Agouron Pharmaceuticals. Viracept (nelfinavir) package insert. La Jolla, CA; 2006.
16. Honda M, Yasouka A, Aoki M, Oka S. A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type 1 infection, suspected due to interaction between nelfinavir and phenytoin. Intern Med 1999;38:302-3.
17. Shelton M, Cloen D, Becker M, Hsyu P, Wilton J, Hewitt R. Evaluation of the pharmacokinetic interactions between phenytoin and nelfinavir in healthy volunteers at steady state. Presented at the 40th interscience conference on antimicrobial agents and chemotherapy, Toronto, Canada, September 17-20, 2000.
18. Miners JO, Birkett DJ. Cytochrome P4502C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998;45:525-38.
19. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:204S-33.
20. GlaxoSmithKline. Epivir (lamivudine) package insert. Research Triangle Park, NC; 2006.
21. GlaxoSmithKline. Retrovir (zidovudine) package insert. Research Triangle Park, NC; 2006.
22. Gilead Sciences Inc. Viread (tenofovir) package insert. Foster City, CA; 2006.
23. GlaxoSmithKline. Ziagen (abacavir) package insert. Research Triangle Park, NC; 2005.
24. Abbott Laboratories. Norvir (ritonavir) package insert. North Chicago, IL; 2007.
25. Roche Laboratories Inc. Invirase (saquinavir) package insert. Nutley, NJ; 2007.
26. Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-6.
27. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999;13:1788-9.
28. Darlington M. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter]. Ann Pharmacother 1997;31:647.
29. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-302.
30. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. Can Med Assoc J 2007;177:357-9.
31. Goldman-Levine JD, Westberg SM. Drug interaction between warfarin and marijuana: two case reports (poster P183D). Presented at the 41st annual midyear clinical meeting of the American Society of Health-System Pharmacists, Anaheim, CA, December 3-7, 2006.